SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Google

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
FROM OUR NEWS FEEDS
How heart failure risk rises after surgery
Wed June 29th - The development of atrial fibrillation following surgery is an important risk factor for heart failure, researchers report today. More
Brain surgery benefits intracranial pressure
Wed June 29th - Craniectomy for intracranial hypertension offers significant benefit, according to new guidance, triggered by British research. More
RECENT COMMENTS
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote:
https://epidemicj17.imascientist.org.uk/2017/06/21... on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
OTHER NEWS OF INTEREST
ENGLEMED HEALTH NEWS

Common drug may fight TB

Thursday July 9th, 2015

A common over-the-counter drug may be effective against tuberculosis, researchers have revealed.

The Swiss study pin-pointed the stomach medicine lansoprazole after tests on thousands of drugs.

Dr Stewart Cole and colleagues at the Federal Institute of Technology Lausanne, Switzerland, used an ingenious method of testing drugs for their efficiency for treating tuberculosis (TB).

The robot system exposes potentially-useful drugs to lung cells that have been grown in the lab and infected with TB. So-called 'high-throughput screens' such as this work through large numbers of drugs quickly and accurately in a day, say the team. If older manual methods were used, the process would take months.

After testing thousands of approved drugs, the scientists identified the antacid drug lansoprazole (sold as Prevacid).

In the journal Nature Communications today (8 July), the team say that lansoprazole works against TB by killing the bacterium after human cells have broken it down into a compound that contains sulphur. Lansoprazole targets a specific enzyme needed for TB to make energy.

Lansoprazole is a proton-pump inhibitor, preventing the stomach from pumping too much acid and avoiding heartburn and ulcers.

Dr Cole says: "Proton-pump inhibitors are both safe and widely sold around the world. Being highly active against drug-resistant strains of M. tuberculosis, this novel class of drugs provides us with an excellent opportunity to treat tuberculosis."

At present, TB is second only to AIDS as the top single-agent killer globally. Due to resistance to TB drugs, there is an urgent need for new treatments. With new drugs taking over ten years to undergo trials and become approved for human use, it is far better for compounds that have already been approved to be repurposed as anti-TB medications.

Rybniker, J. et al. Lansoprazole is an antituberculous prodrug targeting cytochrome bc1. Nature Communications 08 July 2015 doi: 10.1038/ncomms8659

Tags: Europe | Pharmaceuticals | Respiratory | Traveller Health | World Health

Printer friendly page Printer friendly page

Comment on this article:

Name:
Email:
Comment:
<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)
CATEGORIES